418 related articles for article (PubMed ID: 25436468)
1. Consensus review of the treatment of cardiovascular disease in people with hemophilia A and B.
Ferraris VA; Boral LI; Cohen AJ; Smyth SS; White GC
Cardiol Rev; 2015; 23(2):53-68. PubMed ID: 25436468
[TBL] [Abstract][Full Text] [Related]
2. Cardiovascular disease (CVD) in Canadians with haemophilia: Age-Related CVD in Haemophilia Epidemiological Research (ARCHER study).
Minuk L; Jackson S; Iorio A; Poon MC; Dilworth E; Brose K; Card R; Rizwan I; Chin-Yee B; Louzada M
Haemophilia; 2015 Nov; 21(6):736-41. PubMed ID: 26222883
[TBL] [Abstract][Full Text] [Related]
3. Management of cardiovascular disease in haemophilia.
Cayla G; Morange PE; Chambost H; Schved JF
Thromb Res; 2013 Jul; 132(1):8-14. PubMed ID: 23746627
[TBL] [Abstract][Full Text] [Related]
4. Management of antithrombotic therapy for acute coronary syndromes and atrial fibrillation in patients with hemophilia.
Mannucci PM
Expert Opin Pharmacother; 2012 Mar; 13(4):505-10. PubMed ID: 22332913
[TBL] [Abstract][Full Text] [Related]
5. Overcoming the challenges of treating hemophilia in resource-limited nations: a focus on medication access and adherence.
Ghosh K; Ghosh K
Expert Rev Hematol; 2021 Aug; 14(8):721-730. PubMed ID: 34278926
[TBL] [Abstract][Full Text] [Related]
6. Applicability of the European Society of Cardiology guidelines on management of acute coronary syndromes to people with haemophilia - an assessment by the ADVANCE Working Group.
Staritz P; de Moerloose P; Schutgens R; Dolan G;
Haemophilia; 2013 Nov; 19(6):833-40. PubMed ID: 23710576
[TBL] [Abstract][Full Text] [Related]
7. Prevalence and risk factors of atherothrombotic events among 1054 hemophilia patients: a population-based analysis.
Wang JD; Chan WC; Fu YC; Tong KM; Chang ST; Hwang WL; Lin CH; Tsan YT
Thromb Res; 2015 Mar; 135(3):502-7. PubMed ID: 25601170
[TBL] [Abstract][Full Text] [Related]
8. Incidence and survival of cancers among 1,054 hemophilia patients: A nationwide and 14-year cohort study.
Huang YC; Tsan YT; Chan WC; Wang JD; Chu WM; Fu YC; Tong KM; Lin CH; Chang ST; Hwang WL
Am J Hematol; 2015 Apr; 90(4):E55-9. PubMed ID: 25639564
[TBL] [Abstract][Full Text] [Related]
9. Prevalence and risk factors of cardiovascular disease (CVD) events among patients with haemophilia: experience of a single haemophilia treatment centre in the United States (US).
Sharathkumar AA; Soucie JM; Trawinski B; Greist A; Shapiro AD
Haemophilia; 2011 Jul; 17(4):597-604. PubMed ID: 21323799
[TBL] [Abstract][Full Text] [Related]
10. How we manage cardiovascular disease in patients with hemophilia.
Franchini M; Focosi D; Mannucci PM
Haematologica; 2023 Jul; 108(7):1748-1757. PubMed ID: 36700406
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular disease risk factors: prevalence and management in adult hemophilia patients.
Lim MY; Pruthi RK
Blood Coagul Fibrinolysis; 2011 Jul; 22(5):402-6. PubMed ID: 21451396
[TBL] [Abstract][Full Text] [Related]
12. Reducing the risk of atherosclerotic cardiovascular disease in people with hemophilia: the importance of primary prevention.
Dix C; Dolan G; Hunt BJ
J Thromb Haemost; 2024 May; 22(5):1304-1312. PubMed ID: 38309435
[TBL] [Abstract][Full Text] [Related]
13. Cancer detection and management in patients with haemophilia: a retrospective European multicentre study.
Biron-Andreani C; de Moerloose P; D'oiron R; Chambost H; Schved JF; Hermans C
Haemophilia; 2014 Jan; 20(1):78-82. PubMed ID: 23919383
[TBL] [Abstract][Full Text] [Related]
14. Prevention and treatment of atherosclerosis in haemophilia - how to balance risk of bleeding with risk of ischaemic events.
de Raucourt E; Roussel-Robert V; Zetterberg E
Eur J Haematol; 2015 Feb; 94 Suppl 77():23-9. PubMed ID: 25560791
[TBL] [Abstract][Full Text] [Related]
15. Advances in the clinical management of inhibitors in hemophilia A and B.
Leissinger CA
Semin Hematol; 2016 Jan; 53(1):20-7. PubMed ID: 26805903
[TBL] [Abstract][Full Text] [Related]
16. Clinical management of older persons with haemophilia.
Hermans C; de Moerloose P; Dolan G
Crit Rev Oncol Hematol; 2014 Feb; 89(2):197-206. PubMed ID: 23953685
[TBL] [Abstract][Full Text] [Related]
17. Impact of Exercise on Hemophilia.
Zetterberg E; Ljungkvist M; Salim M
Semin Thromb Hemost; 2018 Nov; 44(8):787-795. PubMed ID: 30357762
[TBL] [Abstract][Full Text] [Related]
18. Factor-mimetic and rebalancing therapies in hemophilia A and B: the end of factor concentrates?
Ellsworth P; Ma A
Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):219-225. PubMed ID: 34889356
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular disease prevalence and relevance in haemophilia: a scoping review.
Rizwan I; Minuk L; Jackson S; Iorio A
Haemophilia; 2015 May; 21(3):e156-e166. PubMed ID: 25420604
[TBL] [Abstract][Full Text] [Related]
20. Serpins, New Therapeutic Targets for Hemophilia.
Aymonnier K; Kawecki C; Arocas V; Boulaftali Y; Bouton MC
Thromb Haemost; 2021 Mar; 121(3):261-269. PubMed ID: 32987444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
